Alliance Pharma PLC has announced that the preliminary results for the year ended 31 December 2023 will not be published on 8 May 2024 as previously expected. The audit process is still ongoing, and the company will provide an update on the revised timing in due course. The company reiterates that the details provided in the full year trading update on 29 January 2024 remain accurate.

Alliance Pharma PLC (AIM: APH) is a growing consumer healthcare company with a purpose to empower people to make a positive difference to their health and wellbeing by making trusted and proven brands available worldwide. The company delivers organic growth through investing in priority brands and channels, related innovation, and selective geographic expansion to increase the reach of its brands. The Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region and remains asset-light by outsourcing manufacturing and logistics.

The company may look to enhance its organic growth through selective, complementary acquisitions. Alliance Pharma PLC is headquartered in the UK and is focused on maximizing the value it can bring to its stakeholders and brands. For further information, the company has provided contact details for investor relations and corporate communications.

This update provides insight into the current status of Alliance Pharma PLC's preliminary results and reaffirms the company's commitment to delivering organic growth and expanding its reach through strategic investments and acquisitions.